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Background: Individuals with pre-diabetes are commonly overweight and
benefit from dietary and physical activity strategies aimed at decreasing
body weight and hyperglycemia. Early insulin resistance can be estimated
via the triglyceride glucose index {TyG = Ln [TG (mg/dl) × fasting plasma
glucose (FPG) (mg/dl)/2]} and the hypertriglyceridemic-high waist phenotype
(TyG-waist), based on TyG x waist circumference (WC) measurements. Both
indices may be useful for implementing personalized metabolic management.
In this secondary analysis of a randomized controlled trial (RCT), we aimed to
determine whether the differences in baseline TyG values and TyG-waist phenotype
predicted individual responses to type-2 diabetes (T2D) prevention programs.
Navas-Carretero et al. Triglyceride-Glucose Index and Pre-diabetes Outcome
Methods: The present post-hoc analyses were conducted within the Prevention of
Diabetes through Lifestyle intervention and population studies in Europe and around
the world (PREVIEW) study completers (n = 899), a multi-center RCT conducted in
eight countries (NCT01777893). The study aimed to reduce the incidence of T2D in a
population with pre-diabetes during a 3-year randomized intervention with two sequential
phases. The first phase was a 2-month weight loss intervention to achieve ≥8% weight
loss. The second phase was a 34-month weight loss maintenance intervention with
two diets providing different amounts of protein and different glycemic indices, and two
physical activity programs with different exercise intensities in a 2 x 2 factorial design.
On investigation days, we assessed anthropometrics, glucose/lipid metabolism markers,
and diet and exercise questionnaires under standardized procedures.
Results: Diabetes-related markers improved during all four lifestyle interventions.
Higher baseline TyG index (p < 0.001) was associated with greater reductions in
body weight, fasting glucose, and triglyceride (TG), while a high TyG-waist phenotype
predicted better TG responses, particularly in those randomized to physical activity (PA)
of moderate intensity.
Conclusions: Two novel indices of insulin resistance (TyG and TyG-waist) may allow for
a more personalized approach to avoiding progression to T2D.
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT01777893
reference, identifier: NCT01777893.
Keywords: obesity, pre-diabetes, triglycerides (PubChem CID: 5460048), hypertriglyceridemic-waist phenotype,
precision nutrition, diabetes, carbohydrate metabolism, lipid markers
INTRODUCTION
Pre-diabetes and type 2 diabetes (T2D) with accompanying
metabolic complications, such as hyperglycemia, insulin
resistance, disturbances in lipid metabolism, and pro-
inflammatory processes, are associated with the obesity
pandemic (1, 2). Pre-diabetes is defined as impaired fasting
glucose and/or glucose intolerance or/and elevated glycosylated
hemoglobin (HbA1c) with or without overweight or obesity.
More targeted preventive and management interventions require
investigation with the aim of improved metabolic outcomes (3).
Individuals with obesity, pre-diabetes, and T2D benefit from
lifestyle interventions involving dietary and physical activity
(PA) programs, in which macronutrient distribution, glycemic
index (GI), and fiber consumption are prescribed, within
energy-restricted diets (4–6). In addition, various PA programs
incorporating different exercise types are also beneficial (7, 8).
Abbreviations: ADA, American Diabetes Association; BMI, body mass index;
CID, Clinical Investigation Day; DP, diabetes prevention; EIR, energy intake
reported; FPG, fasting plasma glucose; GI, glycemic index; HbA1c, glycosylated
hemoglobin; HDL cholesterol, high-density lipoprotein cholesterol; LDL
cholesterol, low-density lipoprotein cholesterol; HI, high-intensity; HOMA-IR,
homeostatic model assessment of insulin resistance; HP, high protein; LED,
low-energy diet; MI, moderate intensity; MP, moderate protein; OGTT, oral
glucose tolerance test; PA, physical activity; SOP, Standard Operation Procedure;
SBP, systolic blood pressure; DBP, diastolic blood pressure; T2D, Type 2
diabetes mellitus; TG, Triglyceride; TyG, Triglyceride glucose index; TyG-Waist,
Triglyceride waist circumference index.
Indeed, clinical and epidemiological evidence highlights
independent or combined beneficial effects of manipulating
dietary patterns (quantity and composition of the nutritional
intake) and/or PA (type, intensity, and/or frequency) to
improve glucose homeostasis and reduce diabetes incidence in
people with pre-diabetes (9–11). Specifically, previous lifestyle
interventions, such as the Chinese Da Qing study, the Finnish
Diabetes Prevention Study, and the US, Indian, and Japanese
programs have demonstrated evidence in precluding and
delaying progression to T2D and associated morbidities (12).
Furthermore, a lifestyle approach was shown to reduce all-cause
mortality after 30 years of follow-up (13).
Clinical trials implementing tailored dietary and PA
prescriptions for T2D prevention and management have shown
inter-individual differences depending on the pre-diabetes grade
and associated phenotypes (3). Differences in pretreatment
fasting glucose and insulin status have been reported to be
associated with weight loss success in patients consuming low GI
or fat-rich diets (14). Additionally, data-driven cluster analysis
using variables related to glucose utilization identified five
subgroups within adult-onset diabetes populations providing
some potential for precision nutritional management based on
personalized phenotypes (15).
A scenario of tailored treatment also requires the availability of
simple, reliable, and inexpensive tests to detect insulin resistance.
A novel index based on glucose and TG measurements (the TyG
index), has shown high sensitivity and specificity for identifying
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participants with disturbed insulin function (16), as well as early
diabetes onset in patients with normal fasting glucose (17). Waist
circumference (WC) has also emerged as a useful clinical marker
to distinguish patients according to cardiometabolic risks (18).
A phenotype characterized by both high WC and high TyG
index has been associated consistently with abnormal glucose
and insulin metabolism, with a potential for timely detection of
diabetes and more personalized interventions (19).
The PREVIEW trial (20) explored whether a nutritional
intervention based on different protein intakes and dietary
GI in combination with PA at different intensities, after
an initial weight loss produced long-term benefits for T2D
prevention. All participants had pre-diabetes and were
overweight or obese at baseline. While the incidence of
T2D after 3 years of intervention was very low in all four-
intervention groups, reversion to normal glucose status
varied significantly between the two diet groups (21). In the
current post-hoc analysis, the TyG index and the high WC
high TyG phenotype were tested as a potential predictor of
clinical responses concerning lifestyle modification at the
end (3 years) of the PREVIEW intervention. In addition, we
aimed to specifically identify inter-individual differences in
order to personalize lifestyle prescriptions with a focus on
precision nutrition. We hypothesized that different intervention
patterns may have differential effects depending on the
baseline phenotype.
MATERIALS/SUBJECTS AND METHODS
The present post-hoc analyses were conducted within the
PREVIEW study (NCT01777893) which has been described
elsewhere (20). In summary, this study was a multi-center
randomized trial conducted at eight sites in eight different
countries, aiming to reduce the incidence of T2D in a population
with pre-diabetes (21). The 3-year randomized intervention trial
was implemented in two phases. First, a 2-month weight loss
phase using a commercial low-energy diet (LED) (∼3.4 MJ≪800
kcal≫ per day) to achieve an ≥ 8% bodyweight reduction (22).
Second, a 34-month intervention for weight loss maintenance
encompassing four intervention arms with two diets and two PA
programs using a 2 x 2 factorial design (21). Given the nature of
the study, and the final outcome, it was decided that no control
group would be needed, and benefits of participating in the
intervention were expected in the four intervention arms (20).
The sample size was calculated to be 2,403 subjects, taking into
account data from the Finnish Diabetes Prevention Study (DPS)
and US Diabetes Prevention Program (DPP), and anticipating a
3-year incidence of T2D in our population of 21%, as described
in detail in theMethods article of the PREVIEW Study (20). Once
the potential participants were confirmed eligible, they were
enrolled in the trial and randomized to one of the four treatment
groups. Randomization was stratified by gender and age group
(25–54, and 55–70 years of age), and sequentially assigned from
each stratum to different interventions, hence, securing an even
distribution of gender and age group over the four intervention
arms in each center (20).
A total of 2,326 participants were enrolled in the intervention;
of those 2,223 started the trial, and completed CID7 899. These
participants were adults (25–70 years), overweight [body mass
index (BMI) ≥ 25 kg/m2] men and women with pre-diabetes
as defined by the American Diabetes Association (ADA): fasting
plasma glucose (FPG) of 5.6-−6.9 mmol/L and/or of 7.8-−11.0
mmol/L 2 h after an oral glucose tolerance test (OGTT) of 75 g
glucose when FPG <7.0 mmol/L (23).
Clinical investigation days (CID) were conducted in the
facilities of the intervention centers at baseline (CID1), 2 months
(CID2, end of the first phase), 6 months (CID3), 12 months
(CID4), 18 months (CID5), 24 months (CID6), and 36 months
(CID7, end of the trial). In the present study, only data from
the first and the last visits were used in the analyses. At each
CID, anthropometry, blood samples, 24-h urine samples, 7-days
accelerometer data, dietary records, and questionnaires were
collected. In addition, participants attended 17 group visits led
by trained instructors who supported the acquisition of new
diet and physical activity (PA) habits. A behavior modification
tool (PREMIT) was developed specifically for PREVIEW (24).
All centers had approval from their respective Research Ethics
Boards before starting the trial, and all participants were required
to give written informed consent in their mother tongue before
enrollment (20). The study was conducted in accordance with
the ethical standards of the appropriate ethics committee of each
center, and following the Helsinki Declaration of 1975 as revised
in 1983.
Those participants who reached≥8% body weight loss during
the low-energy diet (LED) phase (n = 1,856), proceeded with
the 34-month weight maintenance phase in one of the four
intervention arms to which they were randomly allocated at the
beginning of the study. The two diets were consumed ad libitum
having received guidance on the proportion of foods to consume
from different food categories in order to achieve the following
nutritional composition: (1) Moderate protein (MP) diet (15% of
energy – E% - from protein, 30 E% fat, 55 E% carbohydrates,
and moderate GI, (2) High protein (HP) diet (25 E% protein,
30 E% fat, 45 E% carbohydrates, and lower GI). The two PA
groups, both with a comparable energy expenditure of >4,200
kJ/week, were as follows: high-intensity (HI) PA (75 min/week)
and moderate-intensity (MI) PA (150 min/week).
Data Collection and Processing
All measures and samples were collected at the intervention
centers during the CIDs following Standard Operation
Procedures (SOP) specifically designed for the study (20).
Blood samples were collected from the antecubital vein after
fasting for 10–12 h. At baseline, month 6, and years 1, 2, and
3, an oral glucose tolerance test (OGTT) with 75 g glucose
was performed, with blood sample collection at every 30min
over the subsequent 2 h, although in the present analysis,
only data from baseline and 3 years are analyzed. Blood
samples were initially stored at −80◦C and then sent to the
central laboratory of the project in Finland (National Institute
for Health and Welfare, Helsinki) for the analysis of FPG,
glycosylated hemoglobin (HbA1c), insulin, homeostatic model
assessment of insulin resistance (HOMA-IR), lipids (total,
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TABLE 1 | Baseline characteristics of PREVIEW completer participants categorized by age and sex.














BMI (kg/m2 ) 33.4 (5.1) 34.4 (5.7) 32.9 (4.8) 33.8 (5.0) 32.4 (4.3) 0.053 <0.001 0.838
Waist circumference (cm) 108.0 (12.8) 104.2 (12.9) 105.3 (11.7) 113.3 (12.6) 113.8 (11.1) <0.001 0.258 0.683
Waist/hip ratio 0.94 (0.09) 0.88 (0.07) 0.91 (0.07) 1.00 (0.07) 1.03 (0.06) <0.001 <0.001 0.777
FPG (mg/ml) 111.1 (11.8) 106.3 (11.6) 112.3 (10.5) 112.7 (14.4) 114.6 (10.2) <0.001 <0.001 0.011
2h glucose (mg/ml) 136.1 (38.3) 130.4 (35.0) 139.9 (39.2) 135.3 (39.1) 138.2 (40.0) 0.576 0.005 0.219
Insulin (mIU/L) 12.3 (7.2) 12.0 (6.8) 11.2 (5.7) 14.8 (11.0) 12.6 (6.4) <0.001 0.007 0.134
HOMA-IR 3.41 (2.24) 3.19 (1.94) 3.15 (1.77) 4.24 (3.71) 3.58 (1.86) <0.001 0.078 0.048
HOMA-beta 11.3 (6.3) 11.6 (6.4) 10.3 (5.1) 13.4 (8.8) 11.3 (5.7) 0.005 <0.001 0.368
TG (mg/dl) 127 (61) 116 (59) 129 (56) 146 (76) 128 (58) 0.004 0.62 <0.001
Total cholesterol (mg/dl) 200 (39) 196 (34) 211 (41) 195 (40) 193 (38) <0.001 0.001 0.001
TyG index 8.76 (0.47) 8.61 (0.49) 8.80 (0.42) 8.89 (0.52) 8.81 (0.43) <0.001 0.002 <0.001
TyG-waist index 947.3 (132.0) 898.0 (130.1) 928.0 (118.8) 1008.2 (132.6) 1003.0 (118.6) <0.001 0.036 0.045
Baecke index 7.29 (1.46) 7.15 (1.52) 7.46 (1.47) 7.19 (1.39) 7.34 (1.41) 0.814 0.015 0.469
Protein intake (g/d) 92.0 (27.4) 88.5 (23.7) 83.5 (19.9) 109.5 (39.0) 98.9 (26.8) <0.001 <0.001 0.137
EIR (kJ/d) 8,690 (2,351) 8,744 (2,326) 7,836 (1,924) 10,003 (2,924) 9,121 (2,075) <0.001 <0.001 0.941
P-values show significant differences and interactions.
aANOVA analysis.
bp-value for interaction.
BMI, Body Mass Index; FPG, Fasting Plasma Glucose; TG, Triglycerides; EIR, Energy intake reported. Bold values mean that p-value is significant (< 0.05).
TABLE 2 | Change in anthropometrical and biochemical variables during the PREVIEW intervention between baseline and after 36-months of intervention (CID7),
categorized by intervention arm.
Metabolic variables Intervention arms
Protein intake Physical activity intensity
Moderate (n = 452) High (n = 447) p for proteina Moderate (n = 448) High (n = 451) p for intensitya
1 BMI (kg/m2 ) −1.64 (2.44) −1.72 (2.62) 0.648 −1.75 (2.58) −1.61 (2.48) 0.42
1 Waist circumference (cm) −3.90 (7.43) −3.42 (8.44) 0.371 −3.99 (7.86) −3.33 (8.03) 0.21
1 FPG (mg/ml) −1.55 (12.92) −1.40 (11.63) 0.855 −1.95 (12.21) −1.01 (12.37) 0.25
1 TG (mg/dl) −17.35 (54.70) −12.07 (49.15) 0.129 −19.72 (56.95) −9.76 (46.21) 0.004
1 TyG −0.15 (0.42) −0.13 (0.39) 0.379 −0.17 (0.44) −0.11 (0.38) 0.023
1 TyG-waist −48.88 (91.12) −42.26 (96.84) 0.292 −51.47 (96.05) −39.74 (91.68) 0.061
1 Baecke index 0.61 (1.15) 0.52 (1.18) 0.365 0.58 (1.05) 0.54 (1.28) 0.682
1 Protein intake (g/day) −7.74 (26.36) −14.67 (28.36) 0.001 −10.25 (26.85) −12.13 (28.27) 0.347
1 EIR (kJ/day) −1886 (2172) −1888 (2319) 0.987 −1763 (2273) −2009 (2214) 0.129
aANOVA 2 × 2.
BMI, Body Mass Index; FPG, Fasting Plasma Glucose; TG, Triglycerides; EIR, Energy Intake reported. Bold values mean that p-value is significant (< 0.05).
HDL and LDL cholesterol, triglycerides -TG-), and C-reactive
protein, as previously described (20). Insulin was measured in
Denmark (University of Copenhagen) on Siemens Immulite
2000 equipment, Siemens Healthcare, Diagnostic products,
Gwynedds, UK following the Immuno-Chemiluminescent
method as previously described (21).
During the CIDs, anthropometric and blood pressure
measurements were also collected (22). Standardized measures
for body weight, body composition (fat mass and fat-free mass
by Bioelectrical Impedance Analysis and DEXA, height, waist,
and hip and thigh circumference were performed in light clothes
by trained researchers, following the guidance described in the
specific SOP developed for PREVIEW. Systolic blood pressure
(SBP) and diastolic blood pressure (DBP) were measured on
the right arm with a validated automatic device after 5–10min
in a resting position (21). The details concerning the analyses
estimating reported energy intake via 4-day food records and
actual protein consumption, accelerometer outcomes, and those
explanations involving the Baecke questionnaire implementation
have been described elsewhere (21).
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TABLE 3 | Regression models concerning the effect of intervention arms (diet and PA groups) on the variation of anthropometrical and biochemical markers as
dependent variables after 36 months of intervention.
Protein intake arms Physical intensity arms p for interaction
β SE P β SE p
1 Body Mass Index (kg/m2)
Model 1 −0.027 0.237 0.910 0.185 0.235 0.432 0.728
Model 2 −0.073 0.232 0.752 0.166 0.231 0.472 0.704
1 Waist circumference (cm)
Model 1 0.757 0.733 0.302 0.908 0.729 0.213 0.648
Model 2 0.673 0.489 0.169 0.441 0.486 0.365 0.951
1 FPG (mg/ml)
Model 1 0.816 1.022 0.425 1.711 1.019 0.093 0.313
Model 2 1.106 0.945 0.242 1.484 0.941 0.115 0.275
1 Triglycerides (mg/ml)
Model 1 4.429 4.124 0.283 7.614 4.110 0.064 0.751
Model 2 5.035 3.758 0.181 6.516 3.743 0.082 0.606
1 TyG index
Model 1 0.023 0.035 0.516 0.058 0.035 0.096 0.808
Model 2 0.030 0.030 0.318 0.046 0.030 0.123 0.666
1 TyG-waist index
Model 1 10.168 8.613 0.238 14.334 8.574 0.095 0.674
Model 2 10.260 5.689 0.072 9.097 5.658 0.108 0.964
Model 1: adjusted by age, sex, and baseline value of dependent variable; Model 2: adjusted by age, sex, baseline value of dependent variable, intervention center, and 1BMI (between
baseline and month 36); FPG: Fasting Plasma Glucose.
The triglyceride glucose index (TyG) and the TyG-
waist circumference index (TyG-waist) were estimated as
surrogate markers of insulin resistance reflecting the individual
physiological status (25). The TyG and TyG-Waist were
calculated using the following formulas: TyG = Ln [TG (mg/dl)
× FPG (mg/dl)/2] (16) and TyG-Waist = TyG index × WC
(cm) (26).
Statistical Methods
Baseline descriptive variables of completers are shown as mean
± SD, with ANOVA used to assess the effect of age and sex
(Table 1). To determine the influence of the intervention within
each arm (diet and PA groups), a 2 x 2 factorial ANOVA
was performed on anthropometrical and biochemical measures
for participants who provided data at baseline and CID7 (3
years). Linear regression models were fitted to changes in
anthropometrical and biochemical measures from baseline to
the end of the study. In the first model, we adjusted for age,
sex, and baseline values of the dependent variable. Intervention
center and change in body mass index (BMI) were added as
covariates in Model 2. These regression analyses also considered
the interaction between diet (energy and protein intake) and PA
(Baecke questionnaires).
Participants were subsequently categorized into two groups
according to the median values of the TyG and TyG-waist index
(8.8 for TyG and 943.6 for TyG-waist, respectively) in order to
assess independently the predictive value of these trygliceride-
related markers and the interaction with the intervention arms.
Linear regression analyses for the difference between baseline and
endpoint were carried out to assess the estimatedmarginal means
for the anthropometric and metabolic markers. The regression
model included the interaction term of the two TyG categories
and each one of the intervention arms (in separate models)
adjusted for age, sex, baseline BMI, and intervention center.
The results of per protocol analysis were preferred because
they better reflect the effects of the intervention when considered
optimally, decreasing the probability of incurring a type II error,
as described elsewhere (27, 28). The statistical per protocol
analyses and calculations were carried out using the statistical
program, R version 4.0.2 (R Core Team, Vienna, Austria)
using the following packages “dplyr,” “psych,” “DescTools,”
“tidyr,” “ggplot2,” “ggpubr,” “MASS,” “multcomp,” “emmeans,”
and RStudio version 1.2.1335. The P < 0.05 was considered
statistically significant.
RESULTS
Baseline characteristics of the completers (n= 899) in the analysis
are shown in Table 1. Sex, age, body mass index (BMI), and
WC correlated as expected with specific metabolic markers of
glucose homeostasis and insulin resistance. Energy intake and
physical activity (PA) (assessed by Baecke estimation) were also
significant predictors. The TyG (p < 0.001) and the TyG-waist
index (p = 0.045) showed significant interactions with age and
sex with a modification of the effects mediated by both factors
(Table 1).
Changes in adiposity, glucose, and TG markers in the
intervention arms from baseline to the end of the study are shown
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FIGURE 1 | Baseline triglyceride glucose index (TyG) prediction value for changes in anthropometric and metabolic outcomes categorized by the intervention groups
of the PREVIEW study. HP, high protein; MP, moderate protein; HI, high intensity; MI, moderate intensity. (A) Fitted change in BMI; (B) Fitted change in waist
circumference; (C) Fitted change in fasting glucose; (D) Fitted change in triglycerides.
in Table 2. There were no differences in changes in glucose,
BMI, and WC among the four interventions groups (Table 2).
However, there were greater reductions in TG (P = 0.004), TyG
(p = 0.023), and TyG-waist (p = 0.061) in the moderate PA
group. The Baecke scores showed that protein intake and energy
intake varied as expected according to the intervention group
(Table 2).
The regression models when adjusted by age, sex, baseline
value of the dependent variable, intervention center, and BMI
changes did not demonstrate any favorable effects of a high
protein diet compared with a moderate protein diet on changes
in fasting glucose (p = 0.242) or circulating TG (p = 0.181)
concentrations (Table 3).
Elevated TyG index at baseline independently and
significantly predicted greater reductions in BMI, FPG,
and TG, but not WC, within each intervention group
(Figure 1). Furthermore, a higher baseline TyG-waist
phenotype was associated with greater decreases in WC,
FPG, and circulating TG, irrespective of the protein level
(Figure 2). Moderate intensity PA (Figure 3) predicted
more favorable metabolic effects than more intensive PA.
Remarkably, those participants with higher baseline TyG-waist
values responded better overall to all lifestyle interventions
(Figures 2, 3).
DISCUSSION
Individuals with pre-diabetes and higher baseline TyG and
TyG-waist phenotypes had superior outcomes in all four
intervention groups in this secondary analysis of the PREVIEW
Study. An elevated TyG index at baseline independently
predicted greater reductions in body mass index (BMI),
FPG, and TG, but not WC, within all four intervention
groups. Furthermore, a higher baseline TyG-waist phenotype
was associated with greater decreases in WC, FPG, and
circulating TG, irrespective of the protein intake. Moderate
physical activity (PA) intensity also appeared to be more
efficacious than high intensity (HI) PA intervention arms with
respect to improvements in TG and WC. However, we did
not find any association between the baseline phenotypes
(TyG index or TyG-waist phenotype) and response to
different treatments.
Obesity and accompanying inflammatory phenomena are
associated with hyperglycemia and insulin resistance, providing
early manifestations that often lead to type-2 diabetes (T2D) and
cardiovascular events (29, 30). Evidence suggests that there are
also differences in prognosis associated with diabetes prevention
and treatment that are due to inter-individual heterogeneity in
glucose tolerance (3). We hypothesized that novel markers of
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FIGURE 2 | Estimated marginal means of changes in metabolic markers depending on baseline TyG-waist categories and dietary protein intake (high vs. moderate
intervention group). (A) Fitted change in BMI; (B) Fitted change in waist circumference; (C) Fitted change in fasting glucose; (D) Fitted change in triglycerides.
insulin resistance, the TyG index and the TyG-waist phenotype,
may help to define and individually categorize patients. Trait
differences among patients may appear depending on personal
(epi)genotype, microbiota, and phenotypic characteristics. A
better understanding of these effects may contribute to tailoring
more effective therapeutic interventions for each individual (31).
Indeed, the growing emphasis on precision nutrition is based
on the premise that clinical variability may require personalized
management (32).
Individualized approaches could be supported by “omics”
technologies (33, 34) and by clustering patients according
to pretreatment weight-for-height, WC, homeostasis model
assessment (HOMA), TyG, and other phenotype-based
algorithms (15, 35, 36). Recently, a machine-learning approach
integrating anthropometrics, blood biochemistry, diet, PA, and
gut microbiota composition accurately forecasted personalized
post-prandial glycemic response to a meal (37). Precision
medicine methodologies may also demonstrate that similar
dietary prescriptions cause different weight loss outcomes
depending on pre-treatment FPG levels (38), while the
precision of clinical monitoring of glucose tolerance and
glycosylated hemoglobin (HbA1c) may be useful for pre-diabetes
management (39).
The implementation of supervised lifestyle interventions in
individuals with pre-diabetes usually focuses on weight loss (5–
10% of body mass) by prescribing energy-controlled dietary
regimes and increases in exercise expenditure in order to reduce
blood glucose levels (40). Less is known about the prescription
of dietary patterns with different macronutrient distribution,
glycemic loads, or restriction of specific foods. Similarly, we
are yet to learn whether the different forms of PA, including
moderate vs. vigorous intensity, resistance training, or other
health behaviors will differentially improve markers of the
metabolic syndrome, including diabetes (41, 42).
Diabetes risk scores and diagnostic algorithms for
personalized precision medicine often use factors, such as
age, sex, family clinical history, WC, BMI, smoking, and alcohol
consumption, dietary and PA habits, as well as blood pressure,
lipid and glucose markers (3, 43). Distinctive pathophysiological
profiles in pre-diabetes phenotypes have been described based
on insulin secretion, insulin sensitivity, and beta-cell dysfunction
assessed by IFG, IGT, and Hb1Ac measurements (40). More
recently, HOMA, TyG, and TyG-waist phenotypes have been
considered with the goal of categorizing different degrees
of insulin resistance and glucose status (17) across different
patients. Circulating fatty acids and TG have been associated
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FIGURE 3 | Estimated marginal means of metabolic markers depending on baseline TyG- waist categories and physical activity (high vs. moderate). (A) Fitted change
in BMI; (B) Fitted change in waist circumference; (C) Fitted change in fasting glucose; (D) Fitted change in triglycerides.
with insulin sensitivity and glucose tolerance, via the generation
of toxic lipids and inflammatory molecules. Changes in cellular
membranes have also been implicated through alterations in
glucose transport and the insulin signaling cascade, endoplasmic
reticulum stress, and reactive oxygen species (44). The glucose-
fatty acid cycle may also be disturbed via circulating lipid species
and inflammatory mediators (45).
Most randomized trials have focused on weight lowering
under energy restriction or dietary recommendations concerning
the nutritional quality of the consumed foods with an emphasis
on fat and carbohydrate/fiber intake as well as general non-
personalized instructions for PA of different types and intensities
(12). However, less scientific evidence is available on the role
of protein intake and its interactions with the level of PA after
weight loss is achieved.
The impact of higher protein intake on TG (a marker of
lipid metabolism) and the TyG index (as an affordable surrogate
of insulin resistance) requires further study. Previous clinical
and lifestyle intervention trials have combined multidisciplinary
prescriptions, including dietary modifications, with or without
energy restriction, with approaches to enhance daily PA or
exercise training, making it difficult to separately discriminate
the role of each factor (diet vs. PA). These difficulties were
overcome in the PREVIEWproject (21), where four experimental
arms were designed: two levels of protein consumption and
two intensities of PA after following a low energy diet (LED)
to induce at least 8% weight loss in 2 months (22). Regarding
protein intake, the main limitation encountered was that the
group following a high protein intake pattern reduced their
protein consumption toward the end of the study, which makes it
difficult to interpret the results. These findings build on previous
studies that suggest replacing sitting with low intensity PA to
produce metabolic benefits that contribute to the prevention
and management of T2D (46). However, despite differences in
instruction [moderate intensity (MI) vs. high intensity (HI) PA],
there were no actual differences in PA intensity. Furthermore,
total PA was as strongly associated with cardiometabolic risk
markers as moderate- to vigorous-intensity physical activity
(MVPA), which implies that the accumulation of total PA over
the day is more important than the intensity of PA in this
population (47).
Secondary analyses in the Look AHEAD and PREDIMED
studies, which were focused on reducing cardiometabolic events
by means of lifestyle interventions revealed improvements in
circulating glucose and TG even after corrections for the
degree of weight change (48, 49). And vice versa, most
of the previous trials revealed that weight loss seems to
be an independent predictor for the prevention of type
2 diabetes mellitus (T2DM), even after adjustments for
diet and PA. The PREVIEW project showed that after a
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period of weight loss, there were no separate effects of diet
composition or PA intensity on the risk of developing T2D
within 3 years. An unexpected finding in PREVIEW was
that significantly fewer participants achieved normoglycemia in
the high protein high intensity (HPHI) PA group, compared
to the other three groups. However, a limitation of the
PREVIEW study is the high attrition rate and the possibility
of selection bias (e.g., in the recruitment of more health-
conscious participants). Nonetheless, the results appear robust
and plausible, providing new evidence that clinicians should
consider in a personalized fashion.
Several clinical and epidemiological studies have reported that
the TyG index was superior to FPG and TG alone in predicting
metabolically unhealthy individuals with fasting glucose levels
under 5.5 mmol/L (16, 17, 36), as well as a role for TyG-
waist for categorizing the hypertriglyceride phenotype (18, 19).
Our findings suggest that the intensity of PA has a role in
the management of glucose and lipid status. Furthermore, the
conceptual framework underlying precision medicine is founded
on assessing inter-individual heterogeneity (50). Accounting
for phenotypic variability requires an understanding of the
markers to be considered (51) and the characteristics of the
intervention (52). In summary, both TyG indices count with
sufficient scientific evidence as markers of insulin resistance,
which showed similar or better precision than FPG, TG, or
WC alone (16, 53). Indeed, these indices are as reliable as
homeostatic model assessment for insulin resistance (HOMA-
IR) regarding insulin resistance, but additionally are simpler,
easier to interpret, and inexpensive than analyzing insulin or
HOMA, as well as more informative than glucose measurements
(16, 54).
In conclusion, individuals with pre-diabetes and higher
baseline TyG and TyG-waist had better outcomes in all
four PREVIEW intervention arms. This is in agreement
with the commonly accepted clinical practice that patients
with extreme features of the metabolic syndrome respond
earlier and better to diverse dietary or pharmacological
treatments. In contrast, we did not find any association
between the baseline phenotype (TyG-index of TyG-waist) and
response to different treatments. A goal of this research
was to prospectively analyze the value of the baseline
insulin resistance status based on both serviceable TyG
tools to characterize patients at baseline and explain future
outcomes, in order to facilitate a personalized prescription
for application in subjects with pre-diabetes based on glucose
tolerance status.
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